MedTrace Logo

Interleukin 38 as a Biomarker for Metabolic Syndrome in Psoriatic Patients

NCT05076812 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 96

Last updated 2021-10-21

No results posted yet for this study

Summary

case control study to compare level of interleukin 38 in patients with psoriasis and patients with metabolic syndrome with healthy control subjects

Conditions

Interventions

DIAGNOSTIC_TEST

measure plasma level of interleukin 38 by ELISA kit

draw 5 ml of venous blood into EDTA tubes and centrifuged then plasma is separated for test

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Principal Investigators

  • yomna a abdellatif, MBBCH

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-31
Primary Completion
2022-05-31
Completion
2022-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05076812 on ClinicalTrials.gov